Renal Insufficiency, Chronic Clinical Trial
Official title:
Underlying Causes of Low Vitamin K Status in Hemodialysis Patients
Studies have shown that patients with chronic kidney disease in hemodialysis have a low
vitamin K status which is believed to be related to an increased risk of atherosclerosis and
increased bleeding tendency. The underlying causes of low vitamin K status in hemodialysis
patients is unknown. Thus, the aim of this study is to investigate why hemodialysis patients
have a low vitamin K status and how to improve it.
This study is composed of five trials. Four of them are based on possible hypotheses to the
low vitamin K status. The hypotheses are:
1. The daily intake of vitamin K is insufficient.
2. Vitamin K is removed from the blood during dialysis.
3. Absorption in the intestines is impaired.
4. The analysis method (dephosphorylated-uncarboxylated MGP) is influenced by the patients'
protein intake.
The purpose of the fifth trial is to investigate solutions to improve the vitamin K status of
hemodialysis. One is to improve vitamin K status through diet with an increased focus on
foods with high concentrations of vitamin K while considering phosphate, potassium and fluid
restrictions. The second is to increase vitamin K status through a daily supplement of 360µg
Menakinon-7.
Studies have reported a low vitamin K status in chronic kidney disease patients in
hemodialysis linked to an increased risk of atherosclerosis and increased bleeding tendency.
The overall aim of this study is to investigate the underlying causes of the reported low
vitamin K status and to improve the patients' vitamin K status through diet and supplement.
The study is divided in 5 sub-trials listed below. Sub-trial 1-4 focuses on determining the
underlying course of low vitamin K status while sub-trial 5 deals with possible solutions to
the reported low vitamin K status.
The analysis method used to determine vitamin K status is dephosphorylated-uncarboxylated
Matrix-Gla-Protein (dp-ucMGP). Dp-ucMGP is the inactive form of the protein MGP whose
activation is vitamin K dependent. The dp-ucMGP analysis method is not a direct measure of
vitamin K status. However, an increased concentration of dp-ucMGP is a manifestation of a low
vitamin K status and vice versa.
Sub-trial 1: Intake of vitamin K Aim: To assess the patients' intake of vitamin K.
Hypothesis: The daily intake of vitamin K is insufficient. Method: Patients are asked to fill
out a food frequency questionnaire (FFQ). The FFQ is based on their intake of different foods
rich in vitamin K during the last month. To compare the results from the FFQ with their
actual vitamin K status a blood sample is collected and analyzed to determine dp-ucMGP.
Participants: 30.
Sub-trial 2: The influence of dialysis Aim: To examine whether vitamin K status is
compromised during dialysis. Hypothesis: Vitamin K is removed from the blood during dialysis.
Method: A blood test is collected before and after dialysis and analyzed to determine
dp-ucMGP. At the end of the dialysis a sample of the remaining dialysis-water is collected
and analyzed to determine dp-ucMGP. Furthermore, the patients will be weighed before and
after dialysis with the purpose of calculating concentrations. Participants: 16 (the analysis
of the dialysis water is done for five patients at first, if the results are useful the
analysis is done for every participant).
Sub-trial 3: Absorption Aim: To investigate whether a decreased absorption can be the cause
of the low vitamin K status. Hypothesis: Absorption in the intestines is impaired. Method: A
D-xylose test is performed. The participants are given a dose of 15g D-xylose dissolved in
water and after one hour a sample of blood is collected to determine D-xylose in serum. Prior
to this trial the patients need to be fasting.The patients are asked to fill out a FFQ
concerning their intake of fat during the last month. Participants: 16
Sub-trial 4: Concentrations of dp-ucMGP is influenced by a low protein intake. Aim: To
determine if a low protein intake influence the dp-ucMGP analysis method. Hypothesis: The
analysis method (dephosphorylated-uncarboxylated MGP) is influenced by the patients' protein
intake. Method: Patients are given a daily protein supplement for 14 days. Before and after
the intervention a blood test is collected and the concentration of dp-ucMGP is determined
and compared. Moreover, the patients are asked to fill out a FFQ concerning their intake of
protein during the last month. Participants: 16
Sub-trial 5: Intervention with vitamin K Aim: To investigate whether a diet or supplement
with tablets is best for improve vitamin K status. Hypothesis: If the intake of vitamin K is
insufficient the diet rich in vitamin K should be sufficient. However, if absorption is
compromised or vitamin K is influenced by dialysis a larger dose of vitamin K might be
necessary. Method: This trial lasts for 15 weeks divided in two periods of six weeks and a
three week wash out period in-between. One period focuses on a diet rich in vitamin K while
dealing with the possible restrictions on phosphate, potassium and fluid for hemodialysis
patients. The intervention in the other period consists of a supplement of 360μg
Menakinon-7/day. Blood samples are collected at the beginning, middle and end of both
periods. These blood samples are analyzed to determine dp-uc-MGP during the intervention
period. Moreover, coagulations factor 2, 7, 10, vitamin A and D status and calcification
propency score analysis will be done as well if the funds allow it. Patients are asked to
fill out a questionnaire concerning physical and mental wellbeing and the presence of
bruising at the beginning and end of both periods to determine whether vitamin K has an
effect. Participants: 24
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT05056727 -
A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
|
Phase 3 | |
| Withdrawn |
NCT01655186 -
A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Effects of Bardoxolone Methyl on Body Composition in Patients With Stage 4 Chronic Kidney Disease and Type 2 Diabetes Mellitus
|
Phase 2 | |
| Completed |
NCT03481686 -
Therapeutic Education of Chronic Renal or Renal Transplant Patient in the Management of EPO Injections
|
N/A | |
| Active, not recruiting |
NCT03672110 -
Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen
|
Phase 3 | |
| Enrolling by invitation |
NCT02237534 -
Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia
|
Phase 4 | |
| Completed |
NCT02126293 -
Correction of Zinc Deficiency in Children With Chronic Kidney Disease and Kidney Transplant
|
Phase 3 | |
| Terminated |
NCT01533545 -
Effect of Epinephrine on Systemic Absorption of Mepivacaine in Uremic Patients
|
N/A | |
| Completed |
NCT03280615 -
Omega 3 Fatty Acids in Patients With Chronic Renal Disease
|
Phase 3 | |
| Completed |
NCT04498156 -
Survey of Patient and Physician Awareness and Values to the Diagnosis and Treatment of Reduced Kidney Function (Chronic Kidney Disease) in Patients With High Blood Sugar Level (Type 2 Diabetes) (AWARE-CKD in T2D)
|
||
| Recruiting |
NCT04020328 -
Leflunomide Plus Low Dose Corticosteroid in Immunoglobulin A (IgA) Nephropathy With Renal Insufficiency
|
Phase 4 | |
| Recruiting |
NCT06366529 -
Explore New Magnetic Resonance Technology in Assessment of Renal Dysfunction
|
||
| Active, not recruiting |
NCT04876963 -
HOLT-ED: Holter-monitoring in End-stage Renal Disease
|
||
| Completed |
NCT03836508 -
Effect of Dialysis Membranes on Inflammatory and Immune Processes in Hemodialysis
|
N/A | |
| Completed |
NCT03250715 -
Effects of Low Level Laser Therapy on Functional Capacity and DNA Damage of Patients With Chronic Kidney Failure
|
N/A | |
| Completed |
NCT03577249 -
Biological Effects of Citrate-buffered Solutions on Dialysis Efficiency and Systemic Inflammation
|
Phase 2/Phase 3 | |
| Completed |
NCT01975818 -
Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
|
Phase 2 | |
| Active, not recruiting |
NCT05766644 -
App-based Education Program for CKD
|
N/A | |
| Active, not recruiting |
NCT02791880 -
Acute Kidney Injury Genomics and Biomarkers in TAVR Study
|
||
| Recruiting |
NCT02947750 -
Neurovascular Transduction During Exercise in Chronic Kidney Disease
|
Phase 2 | |
| Terminated |
NCT02286258 -
Validation of New Markers of Glomerular Filtration Rate: Dota Gadolinium and Calcium EDTA (MultiGFR)
|
Phase 1/Phase 2 |